Diagnostic performance of 14-3-3η and anti-carbamylated protein antibodies in Rheumatoid Arthritis in Han population of Northern China
•Single and multiple indicators can be combined together for identification of RA.•Positive of any two markers or only anti-CCP tend to be diagnosed as RA.•Four indicators were significantly positively correlated with each other. As we already know, Rheumatoid arthritis (RA) cannot be excluded when...
Saved in:
Published in | Clinica chimica acta Vol. 502; pp. 102 - 110 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.03.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •Single and multiple indicators can be combined together for identification of RA.•Positive of any two markers or only anti-CCP tend to be diagnosed as RA.•Four indicators were significantly positively correlated with each other.
As we already know, Rheumatoid arthritis (RA) cannot be excluded when the rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (anti-CCP) is negative. Here, we determined the application value of 14-3-3η protein, anti-carbamylated proteins antibodies (anti-CarP), as well as their potential role to diagnose RA together with RF or anti-CCP.
Serum levels of anti-CCP, RF, 14-3-3η and anti-CarP antibodies were detected in 291 RA patients, 223 patients with autoimmune diseases except RA, and 156 healthy subjects recruited from Han population of Northern China. We examined the differences in the levels of these indicators among groups and compared the correlations between any two of the indicators. At the same time, a total of 12 testing strategies were established for comparison to maximize the diagnostic value.
The levels of RF, anti-CCP, anti-CarP and 14-3-3η were significantly higher in RA patients (12.5;[9.36–15.7], 30.7;[25.7–35.6], 1.90;[1.70–2.01], 15.8;[10.8–20.8], respectively) compared with either interference-control group (1.24;[1.07–1.41], 0.64;[0.42–0.86], 0.51;[0.46–0.57], 0.33;[0.23–0.44], respectively) (p < 0.0001) or healthy-control group (1.03;[0.99–1.08], 0.49;[0.38–0.59], 0.28;[0.21–0.35], 0.55;[0.27–0.85], respectively) (p < 0.0001). Among all 12 detection strategies, the YI and κ value of a novel strategy that either double-positive of any 2 markers or single-positive of anti-CCP can be diagnosed as RA had the highest diagnostic value.
The results of our study demonstrated that in Han population of Northern China, anti-CarP antibodies and 14-3-3η protein can be treated as valuable indicators of RA, especially when combined with RF and anti-CCP, the detection value is maximized. |
---|---|
AbstractList | •Single and multiple indicators can be combined together for identification of RA.•Positive of any two markers or only anti-CCP tend to be diagnosed as RA.•Four indicators were significantly positively correlated with each other.
As we already know, Rheumatoid arthritis (RA) cannot be excluded when the rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (anti-CCP) is negative. Here, we determined the application value of 14-3-3η protein, anti-carbamylated proteins antibodies (anti-CarP), as well as their potential role to diagnose RA together with RF or anti-CCP.
Serum levels of anti-CCP, RF, 14-3-3η and anti-CarP antibodies were detected in 291 RA patients, 223 patients with autoimmune diseases except RA, and 156 healthy subjects recruited from Han population of Northern China. We examined the differences in the levels of these indicators among groups and compared the correlations between any two of the indicators. At the same time, a total of 12 testing strategies were established for comparison to maximize the diagnostic value.
The levels of RF, anti-CCP, anti-CarP and 14-3-3η were significantly higher in RA patients (12.5;[9.36–15.7], 30.7;[25.7–35.6], 1.90;[1.70–2.01], 15.8;[10.8–20.8], respectively) compared with either interference-control group (1.24;[1.07–1.41], 0.64;[0.42–0.86], 0.51;[0.46–0.57], 0.33;[0.23–0.44], respectively) (p < 0.0001) or healthy-control group (1.03;[0.99–1.08], 0.49;[0.38–0.59], 0.28;[0.21–0.35], 0.55;[0.27–0.85], respectively) (p < 0.0001). Among all 12 detection strategies, the YI and κ value of a novel strategy that either double-positive of any 2 markers or single-positive of anti-CCP can be diagnosed as RA had the highest diagnostic value.
The results of our study demonstrated that in Han population of Northern China, anti-CarP antibodies and 14-3-3η protein can be treated as valuable indicators of RA, especially when combined with RF and anti-CCP, the detection value is maximized. As we already know, Rheumatoid arthritis (RA) cannot be excluded when the rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (anti-CCP) is negative. Here, we determined the application value of 14-3-3η protein, anti-carbamylated proteins antibodies (anti-CarP), as well as their potential role to diagnose RA together with RF or anti-CCP. Serum levels of anti-CCP, RF, 14-3-3η and anti-CarP antibodies were detected in 291 RA patients, 223 patients with autoimmune diseases except RA, and 156 healthy subjects recruited from Han population of Northern China. We examined the differences in the levels of these indicators among groups and compared the correlations between any two of the indicators. At the same time, a total of 12 testing strategies were established for comparison to maximize the diagnostic value. The levels of RF, anti-CCP, anti-CarP and 14-3-3η were significantly higher in RA patients (12.5;[9.36-15.7], 30.7;[25.7-35.6], 1.90;[1.70-2.01], 15.8;[10.8-20.8], respectively) compared with either interference-control group (1.24;[1.07-1.41], 0.64;[0.42-0.86], 0.51;[0.46-0.57], 0.33;[0.23-0.44], respectively) (p < 0.0001) or healthy-control group (1.03;[0.99-1.08], 0.49;[0.38-0.59], 0.28;[0.21-0.35], 0.55;[0.27-0.85], respectively) (p < 0.0001). Among all 12 detection strategies, the YI and κ value of a novel strategy that either double-positive of any 2 markers or single-positive of anti-CCP can be diagnosed as RA had the highest diagnostic value. The results of our study demonstrated that in Han population of Northern China, anti-CarP antibodies and 14-3-3η protein can be treated as valuable indicators of RA, especially when combined with RF and anti-CCP, the detection value is maximized. As we already know, Rheumatoid arthritis (RA) cannot be excluded when the rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (anti-CCP) is negative. Here, we determined the application value of 14-3-3η protein, anti-carbamylated proteins antibodies (anti-CarP), as well as their potential role to diagnose RA together with RF or anti-CCP.OBJECTIVESAs we already know, Rheumatoid arthritis (RA) cannot be excluded when the rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (anti-CCP) is negative. Here, we determined the application value of 14-3-3η protein, anti-carbamylated proteins antibodies (anti-CarP), as well as their potential role to diagnose RA together with RF or anti-CCP.Serum levels of anti-CCP, RF, 14-3-3η and anti-CarP antibodies were detected in 291 RA patients, 223 patients with autoimmune diseases except RA, and 156 healthy subjects recruited from Han population of Northern China. We examined the differences in the levels of these indicators among groups and compared the correlations between any two of the indicators. At the same time, a total of 12 testing strategies were established for comparison to maximize the diagnostic value.METHODSerum levels of anti-CCP, RF, 14-3-3η and anti-CarP antibodies were detected in 291 RA patients, 223 patients with autoimmune diseases except RA, and 156 healthy subjects recruited from Han population of Northern China. We examined the differences in the levels of these indicators among groups and compared the correlations between any two of the indicators. At the same time, a total of 12 testing strategies were established for comparison to maximize the diagnostic value.The levels of RF, anti-CCP, anti-CarP and 14-3-3η were significantly higher in RA patients (12.5;[9.36-15.7], 30.7;[25.7-35.6], 1.90;[1.70-2.01], 15.8;[10.8-20.8], respectively) compared with either interference-control group (1.24;[1.07-1.41], 0.64;[0.42-0.86], 0.51;[0.46-0.57], 0.33;[0.23-0.44], respectively) (p < 0.0001) or healthy-control group (1.03;[0.99-1.08], 0.49;[0.38-0.59], 0.28;[0.21-0.35], 0.55;[0.27-0.85], respectively) (p < 0.0001). Among all 12 detection strategies, the YI and κ value of a novel strategy that either double-positive of any 2 markers or single-positive of anti-CCP can be diagnosed as RA had the highest diagnostic value.RESULTThe levels of RF, anti-CCP, anti-CarP and 14-3-3η were significantly higher in RA patients (12.5;[9.36-15.7], 30.7;[25.7-35.6], 1.90;[1.70-2.01], 15.8;[10.8-20.8], respectively) compared with either interference-control group (1.24;[1.07-1.41], 0.64;[0.42-0.86], 0.51;[0.46-0.57], 0.33;[0.23-0.44], respectively) (p < 0.0001) or healthy-control group (1.03;[0.99-1.08], 0.49;[0.38-0.59], 0.28;[0.21-0.35], 0.55;[0.27-0.85], respectively) (p < 0.0001). Among all 12 detection strategies, the YI and κ value of a novel strategy that either double-positive of any 2 markers or single-positive of anti-CCP can be diagnosed as RA had the highest diagnostic value.The results of our study demonstrated that in Han population of Northern China, anti-CarP antibodies and 14-3-3η protein can be treated as valuable indicators of RA, especially when combined with RF and anti-CCP, the detection value is maximized.CONCLUSIONThe results of our study demonstrated that in Han population of Northern China, anti-CarP antibodies and 14-3-3η protein can be treated as valuable indicators of RA, especially when combined with RF and anti-CCP, the detection value is maximized. |
Author | Feng, Limei Zhang, Yuan Liang, Yongming Cui, Liyan |
Author_xml | – sequence: 1 givenname: Yuan surname: Zhang fullname: Zhang, Yuan – sequence: 2 givenname: Yongming surname: Liang fullname: Liang, Yongming – sequence: 3 givenname: Limei surname: Feng fullname: Feng, Limei – sequence: 4 givenname: Liyan surname: Cui fullname: Cui, Liyan email: cliyan@163.com, cuiliyan2006@hotmail.com |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31862264$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1u1DAUhS1URKeFB2CDsmST4L9kYrGqhpYiVSBVZW059jXjUWIH20HqE_SReAueqZ6ZwoJFF5Z1fc93ZJ1zhk588IDQW4Ibgkn3YddorRqKiWgIbTAhL9CK9GtWMy7oCVphjEXdi56corOUdmXkuCOv0CkjfUdpx1fo4ZNTP3xI2elqhmhDnJTXUAVbEV4Xpz-_K-VNOdnVWsVBTfejymCqOYYMzh82QzAOUlWm2y0sk8rBmeoi5m102R3er5Wv5jAvhXXB7-2_hrKH6KvN1nn1Gr20akzw5uk-R9-vLu821_XNt89fNhc3tWYtyzWxrOV80AqEaBWjnTbUcmKNbvuW9LgVVpuBDpbyAQ-95ZhxGGyLewEc94ado_dH3_L9nwukLCeXNIyj8hCWJCmjYs2YYLRI3z1Jl2ECI-foJhXv5d_wioAcBTqGlCLYfxKC5b4guZOlILkvSBIqS0GFWf_HaJcPmeSo3Pgs-fFIQonnl4Mok3ZQujIugs7SBPcM_QgsO6vf |
CitedBy_id | crossref_primary_10_1515_cclm_2021_1136 crossref_primary_10_1038_s41598_022_13750_9 crossref_primary_10_1111_1756_185X_14012 crossref_primary_10_3892_etm_2023_12364 crossref_primary_10_1111_1756_185X_14007 crossref_primary_10_1007_s10067_020_05524_3 crossref_primary_10_1002_jcla_24266 crossref_primary_10_1016_j_ejr_2024_11_002 crossref_primary_10_1080_08820139_2020_1817069 crossref_primary_10_1093_rheumatology_keae297 crossref_primary_10_1016_j_clinbiochem_2021_11_018 crossref_primary_10_3390_diagnostics12071661 |
Cites_doi | 10.1186/s13075-016-1173-0 10.1136/annrheumdis-2013-204154 10.1093/rheumatology/kev250 10.1016/j.phrs.2018.11.009 10.3899/jrheum.140767 10.1186/s13075-015-0536-2 10.1002/art.39664 10.1002/art.40237 10.1002/art.40738 10.1258/000456303321016204 10.1371/journal.pone.0161141 10.1136/annrheumdis-2016-209248 10.5858/2004-128-1078a-EOLITC 10.1038/nrrheum.2011.76 10.1177/0961203317713141 10.1186/s13075-016-0975-4 10.1155/2015/915276 10.1136/annrheumdis-2015-207751 10.1002/art.40562 10.1136/annrheumdis-2015-208870 10.1186/s13075-018-1622-z 10.1007/s10067-017-3807-2 10.1186/s13075-016-1001-6 10.1186/ar4547 10.1002/art.1780310302 10.1073/pnas.1114465108 10.1002/art.37830 10.3899/jrheum.141385 10.3899/jrheum.131446 10.1186/s13075-016-0935-z 10.1136/ard.2010.138461 10.1186/s13075-015-0860-6 10.1002/art.40678 |
ContentType | Journal Article |
Copyright | 2019 Elsevier B.V. Copyright © 2019 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2019 Elsevier B.V. – notice: Copyright © 2019 Elsevier B.V. All rights reserved. |
DBID | AAYXX CITATION NPM 7X8 |
DOI | 10.1016/j.cca.2019.12.011 |
DatabaseName | CrossRef PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry |
EISSN | 1873-3492 |
EndPage | 110 |
ExternalDocumentID | 31862264 10_1016_j_cca_2019_12_011 S0009898119321801 |
Genre | Journal Article |
GroupedDBID | --- --K --M .55 .GJ .~1 0R~ 1B1 1RT 1~. 1~5 29B 4.4 457 4G. 53G 5GY 5VS 6J9 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABBQC ABFNM ABFRF ABGSF ABJNI ABLVK ABMAC ABMZM ABUDA ABXDB ABYKQ ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DOVZS DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q G8K GBLVA HLW HVGLF HZ~ IHE J1W J5H K-O KOM L7B LCYCR LX3 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 R2- RIG RNS ROL RPZ SBG SDF SDG SDP SES SEW SPCBC SSH SSU SSZ T5K WH7 WUQ X7M XPP ZA5 ZGI ~02 ~G- AATTM AAXKI AAYWO AAYXX ABDPE ABWVN ACIEU ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION NPM PKN 7X8 |
ID | FETCH-LOGICAL-c353t-1f3544bcae995a326cd2f41fdc58518059fcdb2bf24b0b8f4034ebf5089e408d3 |
IEDL.DBID | .~1 |
ISSN | 0009-8981 1873-3492 |
IngestDate | Fri Jul 11 07:19:21 EDT 2025 Wed Feb 19 02:31:27 EST 2025 Tue Jul 01 03:32:03 EDT 2025 Thu Apr 24 22:56:59 EDT 2025 Fri Feb 23 02:48:58 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Anti-carbamylated proteins antibodies (anti-CarP) Rheumatoid arthritis (RA) Rheumatoid factor (RF) Anti-cyclic citrullinated peptide antibody (anti-CCP) 14-3-3η |
Language | English |
License | Copyright © 2019 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c353t-1f3544bcae995a326cd2f41fdc58518059fcdb2bf24b0b8f4034ebf5089e408d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 31862264 |
PQID | 2329733932 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2329733932 pubmed_primary_31862264 crossref_primary_10_1016_j_cca_2019_12_011 crossref_citationtrail_10_1016_j_cca_2019_12_011 elsevier_sciencedirect_doi_10_1016_j_cca_2019_12_011 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | March 2020 2020-03-00 2020-Mar 20200301 |
PublicationDateYYYYMMDD | 2020-03-01 |
PublicationDate_xml | – month: 03 year: 2020 text: March 2020 |
PublicationDecade | 2020 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Clinica chimica acta |
PublicationTitleAlternate | Clin Chim Acta |
PublicationYear | 2020 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Gong, Xu, Wu (b0110) 2017; 36 Koppejan, Trouw, Sokolove (b0055) 2016; 68 Shovman, Gilburd, Watad (b0105) 2019; 141 Tholen (b0140) 2004; 128 Bergum, Koro, Delaleu (b0040) 2016; 75 Brink, Verheul, Ronnelid (b0030) 2015; 17 Ross, Sweep (b0135) 2003; 40 Reed, Jiang, Kharlamova (b0160) 2016; 18 Shi, van de Stadt, Levarht (b0025) 2014; 73 van Beers-Tas, Marotta, Boers, Maksymowych, van Schaardenburg (b0100) 2016; 18 Shi, van Steenbergen, van Nies (b0035) 2015; 17 Montes, Regueiro, Perez-Pampin, Boveda, Gomez-Reino, Gonzalez (b0045) 2016; 11 Derksen, Trouw, Huizinga (b0080) 2018; 70 Carrier, Marotta, de Brum-Fernandes (b0115) 2016; 18 Truchetet, Dublanc, Barnetche (b0075) 2017; 69 Verheul, van Erp, van der Woude (b0050) 2016; 75 Ajeganova, van Steenbergen, Verheul (b0070) 2017; 76 Shi, Knevel, Suwannalai (b0015) 2011; 108 Shi, van de Stadt, Levarht (b0020) 2013; 65 van Venrooij, van Beers, Pruijn (b0005) 2011; 7 Wang, Pei, Wang, Sun, Hu, Dou (b0010) 2015; 2015 Verheul, Bohringer, van Delft (b0145) 2018; 70 Aletaha, Neogi, Silman (b0125) 2010; 69 Verheul, Shiozawa, Levarht (b0060) 2015; 54 Regueiro, Rodriguez-Rodriguez, Triguero-Martinez (b0155) 2019; 71 Gan, Trouw, Shi (b0065) 2015; 42 Kilani, Maksymowych, Aitken (b0090) 2007; 34 Massaro, Ceccarelli, Colasanti (b0175) 2018; 27 Maksymowych, Naides, Bykerk (b0150) 2014; 41 Arnett, Edworthy, Bloch (b0130) 1988; 31 Guan, Yang, Bai (b0095) 2019; 49 Pecani, Alessandri, Spinelli (b0165) 2016; 18 Ceccarelli, Perricone, Colasanti (b0170) 2018; 20 Maksymowych, van der Heijde, Allaart (b0085) 2014; 16 Maksymowych, Boire, van Schaardenburg (b0120) 2015; 42 Derksen (10.1016/j.cca.2019.12.011_b0080) 2018; 70 Shi (10.1016/j.cca.2019.12.011_b0015) 2011; 108 Verheul (10.1016/j.cca.2019.12.011_b0050) 2016; 75 Maksymowych (10.1016/j.cca.2019.12.011_b0150) 2014; 41 Maksymowych (10.1016/j.cca.2019.12.011_b0085) 2014; 16 Koppejan (10.1016/j.cca.2019.12.011_b0055) 2016; 68 Kilani (10.1016/j.cca.2019.12.011_b0090) 2007; 34 Shi (10.1016/j.cca.2019.12.011_b0025) 2014; 73 Ross (10.1016/j.cca.2019.12.011_b0135) 2003; 40 van Beers-Tas (10.1016/j.cca.2019.12.011_b0100) 2016; 18 Shi (10.1016/j.cca.2019.12.011_b0020) 2013; 65 Wang (10.1016/j.cca.2019.12.011_b0010) 2015; 2015 Arnett (10.1016/j.cca.2019.12.011_b0130) 1988; 31 Brink (10.1016/j.cca.2019.12.011_b0030) 2015; 17 Pecani (10.1016/j.cca.2019.12.011_b0165) 2016; 18 Shi (10.1016/j.cca.2019.12.011_b0035) 2015; 17 Truchetet (10.1016/j.cca.2019.12.011_b0075) 2017; 69 Montes (10.1016/j.cca.2019.12.011_b0045) 2016; 11 Guan (10.1016/j.cca.2019.12.011_b0095) 2019; 49 Maksymowych (10.1016/j.cca.2019.12.011_b0120) 2015; 42 Reed (10.1016/j.cca.2019.12.011_b0160) 2016; 18 Gong (10.1016/j.cca.2019.12.011_b0110) 2017; 36 Tholen (10.1016/j.cca.2019.12.011_b0140) 2004; 128 Aletaha (10.1016/j.cca.2019.12.011_b0125) 2010; 69 van Venrooij (10.1016/j.cca.2019.12.011_b0005) 2011; 7 Carrier (10.1016/j.cca.2019.12.011_b0115) 2016; 18 Bergum (10.1016/j.cca.2019.12.011_b0040) 2016; 75 Ajeganova (10.1016/j.cca.2019.12.011_b0070) 2017; 76 Shovman (10.1016/j.cca.2019.12.011_b0105) 2019; 141 Verheul (10.1016/j.cca.2019.12.011_b0060) 2015; 54 Verheul (10.1016/j.cca.2019.12.011_b0145) 2018; 70 Ceccarelli (10.1016/j.cca.2019.12.011_b0170) 2018; 20 Gan (10.1016/j.cca.2019.12.011_b0065) 2015; 42 Regueiro (10.1016/j.cca.2019.12.011_b0155) 2019; 71 Massaro (10.1016/j.cca.2019.12.011_b0175) 2018; 27 |
References_xml | – volume: 18 start-page: 37 year: 2016 ident: b0115 article-title: Serum levels of 14-3-3eta protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis publication-title: Arthritis Res. Ther. – volume: 11 year: 2016 ident: b0045 article-title: Anti-carbamylated protein antibodies as a reproducible independent type of rheumatoid arthritis autoantibodies publication-title: PLoS ONE – volume: 76 start-page: 112 year: 2017 end-page: 118 ident: b0070 article-title: The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor publication-title: Ann. Rheum. Dis. – volume: 41 start-page: 2104 year: 2014 end-page: 2113 ident: b0150 article-title: Serum 14-3-3eta is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis publication-title: J. Rheumatol. – volume: 42 start-page: 572 year: 2015 end-page: 579 ident: b0065 article-title: Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis publication-title: J. Rheumatol. – volume: 20 start-page: 126 year: 2018 ident: b0170 article-title: Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus publication-title: Arthritis Res. Ther. – volume: 36 start-page: 2581 year: 2017 end-page: 2587 ident: b0110 article-title: Elevated serum 14-3-3eta protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population publication-title: Clin. Rheumatol. – volume: 27 start-page: 105 year: 2018 end-page: 111 ident: b0175 article-title: Anti-carbamylated protein antibodies in systemic lupus erythematosus patients with articular involvement publication-title: Lupus – volume: 40 start-page: 75 year: 2003 end-page: 78 ident: b0135 article-title: An improved procedure for testing for assay linearity publication-title: Ann. Clin. Biochem. – volume: 49 start-page: 57 year: 2019 end-page: 62 ident: b0095 article-title: Serum 14-3-3eta could improve the diagnostic rate of rheumatoid arthritis and correlates to disease activity publication-title: Ann. Clin. Lab. Sci. – volume: 128 start-page: 1078 year: 2004 ident: b0140 article-title: Evaluation of linearity in the clinical laboratory publication-title: Arch. Pathol. Lab. Med. – volume: 69 start-page: 1580 year: 2010 end-page: 1588 ident: b0125 article-title: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative publication-title: Ann. Rheum. Dis. – volume: 141 start-page: 623 year: 2019 end-page: 626 ident: b0105 article-title: Decrease in 14-3-3eta protein levels is correlated with improvement in disease activity in patients with rheumatoid arthritis treated with Tofacitinib publication-title: Pharmacol. Res. – volume: 42 start-page: 1587 year: 2015 end-page: 1594 ident: b0120 article-title: 14-3-3eta autoantibodies: diagnostic use in early rheumatoid arthritis publication-title: J. Rheumatol. – volume: 18 start-page: 96 year: 2016 ident: b0160 article-title: Antibodies to carbamylated alpha-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies publication-title: Arthritis Res. Ther. – volume: 75 start-page: 1494 year: 2016 end-page: 1500 ident: b0040 article-title: Antibodies against carbamylated proteins are present in primary Sjogren's syndrome and are associated with disease severity publication-title: Ann. Rheum. Dis. – volume: 31 start-page: 315 year: 1988 end-page: 324 ident: b0130 article-title: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis publication-title: Arthritis Rheum. – volume: 17 start-page: 339 year: 2015 ident: b0035 article-title: The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis publication-title: Arthritis Res. Ther. – volume: 34 start-page: 1650 year: 2007 end-page: 1657 ident: b0090 article-title: Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation publication-title: J. Rheumatol. – volume: 71 start-page: 331 year: 2019 end-page: 339 ident: b0155 article-title: Specific association of HLA-DRB1*03 with anti-carbamylated protein antibodies in patients with rheumatoid arthritis publication-title: Arthritis Rheumatol. – volume: 108 start-page: 17372 year: 2011 end-page: 17377 ident: b0015 article-title: Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage publication-title: PNAS – volume: 68 start-page: 2090 year: 2016 end-page: 2098 ident: b0055 article-title: Role of anti-carbamylated protein antibodies compared to anti-citrullinated protein antibodies in indigenous North Americans with rheumatoid arthritis, their first-degree relatives, and healthy controls publication-title: Arthritis Rheumatol. – volume: 54 start-page: 1930 year: 2015 end-page: 1932 ident: b0060 article-title: Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent publication-title: Rheumatology – volume: 73 start-page: 780 year: 2014 end-page: 783 ident: b0025 article-title: Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis publication-title: Ann. Rheum. Dis. – volume: 69 start-page: 2292 year: 2017 end-page: 2302 ident: b0075 article-title: Association of the presence of anti-carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: data from the French ESPOIR Cohort publication-title: Arthritis Rheumatol. – volume: 17 start-page: 25 year: 2015 ident: b0030 article-title: Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage publication-title: Arthritis Res. Ther. – volume: 70 start-page: 2096 year: 2018 end-page: 2097 ident: b0080 article-title: Anti-carbamylated protein antibodies and higher baseline disease activity in rheumatoid arthritis-a replication study in three cohorts: comment on the article by Truchetet et al. publication-title: Arthritis Rheumatol. – volume: 75 start-page: 1575 year: 2016 end-page: 1576 ident: b0050 article-title: Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation publication-title: Ann. Rheum. Dis. – volume: 18 start-page: 276 year: 2016 ident: b0165 article-title: Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases publication-title: Arthritis Res. Ther. – volume: 65 start-page: 911 year: 2013 end-page: 915 ident: b0020 article-title: Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis publication-title: Arthritis Rheum. – volume: 16 start-page: R99 year: 2014 ident: b0085 article-title: 14-3-3eta is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage publication-title: Arthritis Res. Ther. – volume: 2015 year: 2015 ident: b0010 article-title: Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody for juvenile idiopathic arthritis publication-title: J. Immunol. Res. – volume: 70 start-page: 1721 year: 2018 end-page: 1731 ident: b0145 article-title: Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of at-risk individuals publication-title: Arthritis Rheumatol. – volume: 7 start-page: 391 year: 2011 end-page: 398 ident: b0005 article-title: Anti-CCP antibodies: the past, the present and the future publication-title: Nat. Rev. Rheumatol. – volume: 18 start-page: 76 year: 2016 ident: b0100 article-title: A prospective cohort study of 14-3-3eta in ACPA and/or RF-positive patients with arthralgia publication-title: Arthritis Res. Ther. – volume: 18 start-page: 276 year: 2016 ident: 10.1016/j.cca.2019.12.011_b0165 article-title: Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases publication-title: Arthritis Res. Ther. doi: 10.1186/s13075-016-1173-0 – volume: 73 start-page: 780 year: 2014 ident: 10.1016/j.cca.2019.12.011_b0025 article-title: Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2013-204154 – volume: 54 start-page: 1930 year: 2015 ident: 10.1016/j.cca.2019.12.011_b0060 article-title: Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent publication-title: Rheumatology doi: 10.1093/rheumatology/kev250 – volume: 141 start-page: 623 year: 2019 ident: 10.1016/j.cca.2019.12.011_b0105 article-title: Decrease in 14-3-3eta protein levels is correlated with improvement in disease activity in patients with rheumatoid arthritis treated with Tofacitinib publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2018.11.009 – volume: 42 start-page: 572 year: 2015 ident: 10.1016/j.cca.2019.12.011_b0065 article-title: Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis publication-title: J. Rheumatol. doi: 10.3899/jrheum.140767 – volume: 17 start-page: 25 year: 2015 ident: 10.1016/j.cca.2019.12.011_b0030 article-title: Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage publication-title: Arthritis Res. Ther. doi: 10.1186/s13075-015-0536-2 – volume: 68 start-page: 2090 year: 2016 ident: 10.1016/j.cca.2019.12.011_b0055 article-title: Role of anti-carbamylated protein antibodies compared to anti-citrullinated protein antibodies in indigenous North Americans with rheumatoid arthritis, their first-degree relatives, and healthy controls publication-title: Arthritis Rheumatol. doi: 10.1002/art.39664 – volume: 69 start-page: 2292 year: 2017 ident: 10.1016/j.cca.2019.12.011_b0075 article-title: Association of the presence of anti-carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: data from the French ESPOIR Cohort publication-title: Arthritis Rheumatol. doi: 10.1002/art.40237 – volume: 71 start-page: 331 year: 2019 ident: 10.1016/j.cca.2019.12.011_b0155 article-title: Specific association of HLA-DRB1*03 with anti-carbamylated protein antibodies in patients with rheumatoid arthritis publication-title: Arthritis Rheumatol. doi: 10.1002/art.40738 – volume: 40 start-page: 75 year: 2003 ident: 10.1016/j.cca.2019.12.011_b0135 article-title: An improved procedure for testing for assay linearity publication-title: Ann. Clin. Biochem. doi: 10.1258/000456303321016204 – volume: 11 year: 2016 ident: 10.1016/j.cca.2019.12.011_b0045 article-title: Anti-carbamylated protein antibodies as a reproducible independent type of rheumatoid arthritis autoantibodies publication-title: PLoS ONE doi: 10.1371/journal.pone.0161141 – volume: 75 start-page: 1575 year: 2016 ident: 10.1016/j.cca.2019.12.011_b0050 article-title: Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2016-209248 – volume: 128 start-page: 1078 year: 2004 ident: 10.1016/j.cca.2019.12.011_b0140 article-title: Evaluation of linearity in the clinical laboratory publication-title: Arch. Pathol. Lab. Med. doi: 10.5858/2004-128-1078a-EOLITC – volume: 7 start-page: 391 year: 2011 ident: 10.1016/j.cca.2019.12.011_b0005 article-title: Anti-CCP antibodies: the past, the present and the future publication-title: Nat. Rev. Rheumatol. doi: 10.1038/nrrheum.2011.76 – volume: 27 start-page: 105 year: 2018 ident: 10.1016/j.cca.2019.12.011_b0175 article-title: Anti-carbamylated protein antibodies in systemic lupus erythematosus patients with articular involvement publication-title: Lupus doi: 10.1177/0961203317713141 – volume: 18 start-page: 76 year: 2016 ident: 10.1016/j.cca.2019.12.011_b0100 article-title: A prospective cohort study of 14-3-3eta in ACPA and/or RF-positive patients with arthralgia publication-title: Arthritis Res. Ther. doi: 10.1186/s13075-016-0975-4 – volume: 2015 year: 2015 ident: 10.1016/j.cca.2019.12.011_b0010 article-title: Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody for juvenile idiopathic arthritis publication-title: J. Immunol. Res. doi: 10.1155/2015/915276 – volume: 75 start-page: 1494 year: 2016 ident: 10.1016/j.cca.2019.12.011_b0040 article-title: Antibodies against carbamylated proteins are present in primary Sjogren's syndrome and are associated with disease severity publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2015-207751 – volume: 70 start-page: 1721 year: 2018 ident: 10.1016/j.cca.2019.12.011_b0145 article-title: Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of at-risk individuals publication-title: Arthritis Rheumatol. doi: 10.1002/art.40562 – volume: 76 start-page: 112 year: 2017 ident: 10.1016/j.cca.2019.12.011_b0070 article-title: The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor publication-title: Ann. Rheum. Dis. doi: 10.1136/annrheumdis-2015-208870 – volume: 20 start-page: 126 year: 2018 ident: 10.1016/j.cca.2019.12.011_b0170 article-title: Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus publication-title: Arthritis Res. Ther. doi: 10.1186/s13075-018-1622-z – volume: 34 start-page: 1650 year: 2007 ident: 10.1016/j.cca.2019.12.011_b0090 article-title: Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation publication-title: J. Rheumatol. – volume: 36 start-page: 2581 year: 2017 ident: 10.1016/j.cca.2019.12.011_b0110 article-title: Elevated serum 14-3-3eta protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population publication-title: Clin. Rheumatol. doi: 10.1007/s10067-017-3807-2 – volume: 18 start-page: 96 year: 2016 ident: 10.1016/j.cca.2019.12.011_b0160 article-title: Antibodies to carbamylated alpha-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies publication-title: Arthritis Res. Ther. doi: 10.1186/s13075-016-1001-6 – volume: 16 start-page: R99 year: 2014 ident: 10.1016/j.cca.2019.12.011_b0085 article-title: 14-3-3eta is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage publication-title: Arthritis Res. Ther. doi: 10.1186/ar4547 – volume: 31 start-page: 315 year: 1988 ident: 10.1016/j.cca.2019.12.011_b0130 article-title: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis publication-title: Arthritis Rheum. doi: 10.1002/art.1780310302 – volume: 108 start-page: 17372 year: 2011 ident: 10.1016/j.cca.2019.12.011_b0015 article-title: Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage publication-title: PNAS doi: 10.1073/pnas.1114465108 – volume: 65 start-page: 911 year: 2013 ident: 10.1016/j.cca.2019.12.011_b0020 article-title: Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis publication-title: Arthritis Rheum. doi: 10.1002/art.37830 – volume: 42 start-page: 1587 year: 2015 ident: 10.1016/j.cca.2019.12.011_b0120 article-title: 14-3-3eta autoantibodies: diagnostic use in early rheumatoid arthritis publication-title: J. Rheumatol. doi: 10.3899/jrheum.141385 – volume: 41 start-page: 2104 year: 2014 ident: 10.1016/j.cca.2019.12.011_b0150 article-title: Serum 14-3-3eta is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis publication-title: J. Rheumatol. doi: 10.3899/jrheum.131446 – volume: 18 start-page: 37 year: 2016 ident: 10.1016/j.cca.2019.12.011_b0115 article-title: Serum levels of 14-3-3eta protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis publication-title: Arthritis Res. Ther. doi: 10.1186/s13075-016-0935-z – volume: 69 start-page: 1580 year: 2010 ident: 10.1016/j.cca.2019.12.011_b0125 article-title: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative publication-title: Ann. Rheum. Dis. doi: 10.1136/ard.2010.138461 – volume: 17 start-page: 339 year: 2015 ident: 10.1016/j.cca.2019.12.011_b0035 article-title: The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis publication-title: Arthritis Res. Ther. doi: 10.1186/s13075-015-0860-6 – volume: 70 start-page: 2096 year: 2018 ident: 10.1016/j.cca.2019.12.011_b0080 article-title: Anti-carbamylated protein antibodies and higher baseline disease activity in rheumatoid arthritis-a replication study in three cohorts: comment on the article by Truchetet et al. publication-title: Arthritis Rheumatol. doi: 10.1002/art.40678 – volume: 49 start-page: 57 year: 2019 ident: 10.1016/j.cca.2019.12.011_b0095 article-title: Serum 14-3-3eta could improve the diagnostic rate of rheumatoid arthritis and correlates to disease activity publication-title: Ann. Clin. Lab. Sci. |
SSID | ssj0004061 |
Score | 2.3658519 |
Snippet | •Single and multiple indicators can be combined together for identification of RA.•Positive of any two markers or only anti-CCP tend to be diagnosed as... As we already know, Rheumatoid arthritis (RA) cannot be excluded when the rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (anti-CCP) is... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 102 |
SubjectTerms | 14-3-3η Anti-carbamylated proteins antibodies (anti-CarP) Anti-cyclic citrullinated peptide antibody (anti-CCP) Rheumatoid arthritis (RA) Rheumatoid factor (RF) |
Title | Diagnostic performance of 14-3-3η and anti-carbamylated protein antibodies in Rheumatoid Arthritis in Han population of Northern China |
URI | https://dx.doi.org/10.1016/j.cca.2019.12.011 https://www.ncbi.nlm.nih.gov/pubmed/31862264 https://www.proquest.com/docview/2329733932 |
Volume | 502 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hkNpeqgJ9bAvIlTghpcSv3fiIFtBCBYcKJG5WHNsiFU1WdPfQS6_9Sf0X_U2dcZJFPcChhxzi2LHlmcx8zrwA9kMwpRCFzowfm0xF_NJN7g2eUjhHhaalMhQofHE5nl2r8xt9swbTIRaG3Cp72d_J9CSt-5bDfjcP53VNMb45FT_kBEF4kWK4lJoQl3_6-eDmQQprqKZGvQfLZvLxwuWTd5dJfwQ5f0w3PYY9kw46fQUve_DIjrr1bcJaaLbg-XSo2bYFzy56U_k2_DrunOiwK5s_RAewNjKuMpnJP79Z2Xi8FnVWkdXh2487BJ6epdQNdZOeuJa8DBnefbkNS0S3be1p_tuUC4naZ2XD5qsqYPT6ZAoK9w1Ltblfw_XpydV0lvVVF7JKarnIeJRaKVeVwRhdIrqrvIiKR1-RBbFAOBYr74SLQrncFVHlUgUXEeiZoPLCyzew3rRNeAcMoZpzGgGhc_jGwpS6KpQQeSmcmBgtRpAP-22rPiU5Vca4s4Pv2VeLJLJEIsuFRRKN4GA1ZN7l43iqsxqIaP9hKov64qlhHweCW6QfWVDKJrTL7xbhp5lIiQw3grcdJ6xWgcJxTFHJ7_9v0g_wQtBRPrm37cD64n4ZdhHvLNxeYug92Dg6-zy7_AtJWP15 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4hkEovFaWvLX24Uk-VUuLXEh-rbdHyWA4VSNysOLZFEE1WdPfQS6_9SfyL_qbOOMmiHuDAIYc4fskz9nzOvAA-hmBKIQqdGT82mYq4003uDd5SOEeBpqUy5Cg8OxlPz9ThuT5fg8ngC0Nmlf3Z353p6bTuS3b71dyd1zX5-OaU_JATBOEF-XBtKNy-lMbg8-9bOw-SWEM6Nao-qDaTkRfOn8y7TPolyPldwuku8JmE0P4WPOnRI_vSTfAprIVmGzYnQ9K2bXg063Xlz-DP186KDquy-a17AGsj4yqTmfx7w8rG47Oos4rUDj9-XSHy9CzFbqib9MW1ZGbI8O37RVgivG1rT-NfpGBIVD4tGzZfpQGj7pMuKFw3LCXnfg5n-99OJ9OsT7uQVVLLRcaj1Eq5qgzG6BLhXeVFVDz6ilSIBeKxWHknXBTK5a6IKpcquIhIzwSVF16-gPWmbcIrYIjVnNOICJ3DHgtT6qpQQuSlcGLPaDGCfFhvW_UxySk1xpUdjM8uLZLIEoksFxZJNIJPqybzLiDHfZXVQET7H1dZFBj3NfswENwi_UiFUjahXf60iD_NnpTIcSN42XHCahZ4Oo7JLfn1wwZ9D5vT09mxPT44OdqBx4Lu9cnW7Q2sL66X4S2Cn4V7l5j7Hwjn_wc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diagnostic+performance+of+14-3-3%CE%B7+and+anti-carbamylated+protein+antibodies+in+Rheumatoid+Arthritis+in+Han+population+of+Northern+China&rft.jtitle=Clinica+chimica+acta&rft.au=Zhang%2C+Yuan&rft.au=Liang%2C+Yongming&rft.au=Feng%2C+Limei&rft.au=Cui%2C+Liyan&rft.date=2020-03-01&rft.eissn=1873-3492&rft.volume=502&rft.spage=102&rft_id=info:doi/10.1016%2Fj.cca.2019.12.011&rft_id=info%3Apmid%2F31862264&rft.externalDocID=31862264 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-8981&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-8981&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-8981&client=summon |